Inclusion Criteria:  Men aged >=18 with histologically confirmed low or intermediate risk prostate cancer per NCCN guidelines. Low risk subjects per NCCN guidelines require a high risk Decipher score (≥0.60). ECOG 0 - 1 IPSS < 18 Ability to receive MRI-guided radiotherapy. Ability to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire. Patients with a prior or concurrent disease whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. Note: Any patient with a cancer (other than keratinocyte carcinoma or carcinoma in situ or low-grade non-muscle invasive bladder cancer) who has been disease-free for less than 3 years must contact the Principal Investigator.  Exclusion Criteria:  Prior history of receiving pelvic radiotherapy. Patient with history of inflammatory bowel disease. Unilateral or bilateral hip replacements. History of bladder neck or urethral stricture. TURP < 6 months prior to radiotherapy Metastatic (pelvic nodal or distant) disease on CT, Bone, Fluciclovine, and/or PSMA PET scan